Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

12/17/2019, Tuesday

Media Contacts:
Kristy Marks
Kristy.marks@bausch.com
(908) 927-0683

Teresa Panas
teresa@tgpcomm.com
(973) 809-8590

 

BAUSCH + LOMB INITIATES CLINICAL TRIAL EVALUATING NEW COHESIVE OPHTHALMIC VISCOSURGICAL DEVICE (OVD)

Investigational OVD Now the Second in the Company’s Pipeline

BRIDGEWATER, N.J., Dec. 17, 2019 – Bausch + Lomb, a leading global eye health company, announced today that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device (OVD) intended to provide surgeons with a new option in the continuum of cohesive and dispersive viscoelastics.

“This is the second new OVD that we are working to bring to the U.S. market,” said Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb. “We know that surgeons need a variety of viscosurgical properties from which to choose based on their clinical techniques and preferences, and we are committed to providing these options as part of our broader commitment to continuously deliver meaningful innovation to our customers and their patients.”

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.

###

© 2019 Bausch & Lomb Incorporated or its affiliates.
NPR.0275.USA.19

Print

Number of views (1662)/Comments (0)

x